JP2022500076A5 - - Google Patents
Info
- Publication number
- JP2022500076A5 JP2022500076A5 JP2021537505A JP2021537505A JP2022500076A5 JP 2022500076 A5 JP2022500076 A5 JP 2022500076A5 JP 2021537505 A JP2021537505 A JP 2021537505A JP 2021537505 A JP2021537505 A JP 2021537505A JP 2022500076 A5 JP2022500076 A5 JP 2022500076A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- fusion protein
- mutations
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18193663.4 | 2018-09-11 | ||
| EP18193663 | 2018-09-11 | ||
| EP19160485.9 | 2019-03-04 | ||
| EP19160485 | 2019-03-04 | ||
| PCT/EP2019/074153 WO2020053239A1 (en) | 2018-09-11 | 2019-09-11 | Epitope tags recognized by specific binders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500076A JP2022500076A (ja) | 2022-01-04 |
| JP2022500076A5 true JP2022500076A5 (enExample) | 2022-09-16 |
| JP7623006B2 JP7623006B2 (ja) | 2025-01-28 |
Family
ID=68138006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537505A Active JP7623006B2 (ja) | 2018-09-11 | 2019-09-11 | 特異的結合剤により認識されるエピトープタグ |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US12365705B2 (enExample) |
| EP (1) | EP3849996B1 (enExample) |
| JP (1) | JP7623006B2 (enExample) |
| CN (1) | CN113195516B (enExample) |
| WO (1) | WO2020053239A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023214781A1 (en) * | 2022-02-02 | 2024-08-15 | BioNTech SE | Cyclic epitope tags |
| CA3250175A1 (en) * | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and Methods for Targeted Cell Administration |
| JP2025507295A (ja) * | 2022-02-02 | 2025-03-18 | バイオエヌテック エスエー | 細胞への核酸の標的化送達のための薬剤および方法 |
| AU2023271317A1 (en) | 2022-05-16 | 2024-11-07 | Byondis B.V. | Novel masked antibodies |
| CN117802045A (zh) | 2022-09-30 | 2024-04-02 | 北京恩康医药有限公司 | 一种工程化细胞外囊泡的构建及其应用 |
| US12565665B2 (en) | 2022-12-21 | 2026-03-03 | Trustees Of Boston University | Compositions and methods for controlled mRNA translation and stability |
| JPWO2024172152A1 (enExample) * | 2023-02-17 | 2024-08-22 | ||
| WO2025021277A1 (en) * | 2023-07-21 | 2025-01-30 | BioNTech SE | Agents and methods for targeted delivery of cytokines to immune cells |
| EP4520768A1 (en) | 2023-09-06 | 2025-03-12 | BioNTech SE | Vhh-ch3 fusion proteins |
| WO2025078418A1 (en) | 2023-10-10 | 2025-04-17 | Nano Tag Biotechnologies Gmbh | Humanized single-domain antibodies binding to epitope tags |
| AU2024360228A1 (en) | 2023-10-11 | 2026-03-19 | BioNTech SE | Agents and methods for targeted delivery of immune effector cells |
| WO2025219955A1 (en) * | 2024-04-17 | 2025-10-23 | BioNTech SE | Soluble tcrs and methods of use thereof |
| CN120923600A (zh) * | 2024-05-09 | 2025-11-11 | 福建医科大学 | 一种超稳定红色荧光蛋白 |
| US20260015401A1 (en) * | 2024-07-10 | 2026-01-15 | Angeles Therapeutics, Inc. | Compositions and methods comprising epitopes and polypeptides |
| WO2026019685A1 (en) * | 2024-07-17 | 2026-01-22 | Harpoon Therapeutics, Inc. | Her2 targeting trispecific protein for treatment of cancer |
| CN118909142A (zh) * | 2024-08-07 | 2024-11-08 | 北京爱思益普生物科技股份有限公司 | Irak4蛋白的制备方法及其所采用的融合蛋白 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1621554T4 (da) * | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US20040014955A1 (en) * | 2001-12-17 | 2004-01-22 | Carlos Zamudio | Identification of essential genes of cryptococcus neoformans and methods of use |
| EP1558645B1 (en) * | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| CL2008002092A1 (es) * | 2007-07-20 | 2009-05-29 | Hoffmann La Roche | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. |
| US7678883B2 (en) * | 2007-07-25 | 2010-03-16 | E.I. Du Pont De Nemours And Company | Solubility tags for the expression and purification of bioactive peptides |
| GB201008682D0 (en) | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
| PL3215614T3 (pl) * | 2014-11-03 | 2019-12-31 | Merck Patent Gmbh | Rozpuszczalne białka fuzyjne inteiny i sposoby oczyszczania biocząsteczek |
| EP3168306A1 (en) | 2015-11-16 | 2017-05-17 | ChromoTek GmbH | Epitope tag and method for detection and/or purification of tagged polypeptides |
-
2019
- 2019-09-11 JP JP2021537505A patent/JP7623006B2/ja active Active
- 2019-09-11 EP EP19782903.9A patent/EP3849996B1/en active Active
- 2019-09-11 WO PCT/EP2019/074153 patent/WO2020053239A1/en not_active Ceased
- 2019-09-11 CN CN201980074346.7A patent/CN113195516B/zh active Active
- 2019-09-11 US US17/274,755 patent/US12365705B2/en active Active
-
2025
- 2025-06-10 US US19/234,249 patent/US20260103489A1/en active Pending
- 2025-06-10 US US19/234,256 patent/US20260103490A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500076A5 (enExample) | ||
| JP7623006B2 (ja) | 特異的結合剤により認識されるエピトープタグ | |
| Kipriyanov et al. | Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment–core streptavidin fusion | |
| Dübel et al. | Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv) | |
| JP2020186248A5 (enExample) | ||
| JP2017518748A5 (enExample) | ||
| JP2019521643A5 (enExample) | ||
| US11384141B2 (en) | Serum albumin binding antibodies for tuneable half-life extension of biologics | |
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| JP2018532372A5 (enExample) | ||
| WO2021092075A1 (en) | IL-2RβγC BINDING COMPOUNDS | |
| JP2014502149A5 (enExample) | ||
| CN105968204A (zh) | 一种抗前列腺特异性膜抗原的单域重链抗体 | |
| US20240027467A1 (en) | Nanobody Exchange Chromatography | |
| CN105968201A (zh) | 针对前列腺特异性膜抗原的单域重链抗体 | |
| JP5042237B2 (ja) | 血小板抗原特異抗体の結合を中和するペプチドアプタマー並びにそれを含む診断及び治療への応用 | |
| WO2021207613A1 (en) | Frb antibodies | |
| JP2022520550A5 (enExample) | ||
| JP2019523782A5 (enExample) | ||
| Käkönen et al. | Purification and characterization of recombinant osteocalcin fusion protein expressed inEscherichia coli | |
| US7741053B2 (en) | Processes for purification of recombinant proteins | |
| CN104311654A (zh) | 一种cide3多肽及其抗体的制备和应用 | |
| Chen | In vitro production of multimeric and multispecific nanobodies with the peptidisc technology | |
| CN107629112B (zh) | 一种高亲和性lc3蛋白靶向肽及其应用 | |
| Aguilar et al. | MAP dendrimer elicits antibodies for detecting rat and mouse GH‐binding proteins |